GCV Symposium 2017
Skip Content

5 December 2013

Juno brings big guns against cancer

Juno Therapeutics – a joint venture between Seattle and New York research centres – receives a massive $120m in series A backing.

Author: Gregg Bayes-Brown, editor

Several leading cancer research centres have partnered to launch Juno Therapeutics, a cancer immunotherapy startup, which has received one of the largest series A rounds in history.

Seattle-based Fred Hutchinson Cancer Research Centre and the Seattle Children’s Research Institute partnered on the New York City-based Memorial Sloan-Kettering Cancer Centre (MSKCC) to launch the venture.

Investors include venture firm and former spin-out of the University of Chicago ARCH Venture Partners (Chicago remains a partner and investor) and the Alaska Permanent Fund, a state-managed investment vehicle which uses 25% of Alaska’s oil money as a nest egg for future generations once oil runs out in the state (last year worth $42.1bn).

Juno’s technology hinges around T cells, one of the body’s natural defence mechanisms. The company intends to reprogram T Cells to recognise and target cancer cells to deliver precise immunological payload, essentially turning a patient’s own immune system into a powerful anti-tumour weapon.

Hans Bishop, Juno chief executive, said: “Juno brings together renowned scientists and exceptional investment partners to launch and quickly scale an enterprise that will deliver cutting-edge cancer immunotherapy. It is a completely unique opportunity that holds the potential to truly save lives while transforming how we treat cancer.”

Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.

  • Linkedin
  • Mail
  • Rssfeed
Trial Subscribe now

Latest Magazine

GCV Symposium 2017

Editor’s picks

Most popular


23 April 2017

UniVenture Visions 2017 Symposium – Hong Kong

The Coller Institute of Venture and the AUTM Asia 2017 Conference have announced UniVenture Visions, an exclusive symposium that shall trigger the thinking and discussion necessary to evolve research universities…

23 May 2017

GCV Symposium 2017 - London

Join 400+ business leaders from the corporate venturing and wider high growth business ecosystem for the two-day 2017 GCV Symposium.